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Abstract: Adenomatoid tumors are responsible for 30% of all paratesticular masses. These are usually asymptomatic, slow growing 
masses. They are benign tumors comprising of cords and tubules of cuboidal to columnar cells with vacuolated cytoplasm and fibrous 
stroma. They are considered to be of mesothelial origin supported by histochemical studies and genetic analysis of Wilms tumor 
1 gene expression. Excision biopsy is both diagnostic and therapeutic procedure. The main clinical consideration is accurate diagnosis 
preventing unnecessary orchiectomy. Diagnostic studies include serum tumor markers (negative alpha fetoprotein, beta HCG, LDH) 
ultrasonography (hypoechoic and homogenous appearance) and frozen section.
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Introduction
Adenomatoid  tumors  are  rare  and  benign  tumors 
of the male and female genital tract. They are also 
known by the pseudonym of “benign mesothelioma” 
of the intrascrotal tumors but they usually present as 
extra testicular masses, they are the most common 
paratesticular neoplasm and account for approximately 
30%  of  all  paratesticular  masses.1,2  Occasionally 
they occur as an intratesticular mass. Although the 
histiogenesis of this rare neoplasm has been a source 
of controversy and it is now generally agreed that 
they are of mesothelial origin. Recent studies have 
provided evidence in favor of a mesothelial origin.3 
The Wilms tumors 1 WT1 gene which is involved 
in normal growth and differentiation of mesothelial 
tissue,  gonads,  kidney  and  spleen  has  also  been 
implicated in adenomatoid tumor development further 
supporting its mesothelial origin.4
clinical Features
Adenomatoid tumors show a predilection for white 
males they appear mostly in the third to fifth decades, 
mean age is 36 years.2,5 Adenomatoid tumor usually 
arises  in  male  and  female  genital  tract  organs.  In 
females  they  are  found  in  uterus,  fallopian  tubes 
and  ovarian  hilus.  In  the  male  they  occur  in  the 
epididymis, spermatic cord, prostate and ejaculatory 
duct. Mostly they arise within or around the lower 
or upper pole of the epididymis with equal frequency 
on  both  sides.6  Intratesticular  adenomatoid  tumor 
originates in the tunica albugines resulting in their 
peripheral location. They may also be found in the 
tunica vaginalis and rete testis.2 Adenomatoid tumors 
are the most common paratesticular neoplasms and 
account for approximately 30% of all paratesticular 
masses  and  unusual  locations  include  the  adrenal 
gland, pleura and lymph nodes resulting in diagnostic 
difficulties.1,4
They present either as an incidental finding or a slow 
growing scrotal mass. Enlargement is usually painless 
with normal scrotal skin and surrounding adenexa. 
Mostly they have been present asymptomatically for 
several years and are uniformly benign. Rarely it has 
presented with testicular pain and inflammation and 
also as an incidental finding in a chronic myeloid 
leukemia (CML) patient on imatinib therapy, but its 
implications for long term imatinib therapy are as 
yet undetermined.7 Adenomatoid tumors are usually 
small  in  size  rarely  exceeding  2 cmm3  (range  is 
0.5–5.0 cm). On ultrasonography they are typically 
appear as hyperechoic and homogeneous. Although 
they may also be hypoechoic.2
pathology
Gross
On gross appearance these tumors are usually small, 
solid, firm, grayish white to tan and poorly to well 
circumscribed  masses.  They  are  situated  between 
testicular  tissue  and  tunica  albugunia  or  lamina 
parietalis  of  tunica  vaginalis  testes. They  can  also 
appear as flattened and plaque like masses. On frozen 
section appearance shows atrophic testes with fibrous 
stromal proliferation.8
Extra  genital  adenomatoid  tumors  have  been 
reported in ovaries and uterus. Multiple adenomatoid 
tumors  have  been  reported  in  mesocolon  and 
omentum,  other  reported  locations  include  adrenal 
gland, liver, peritoneum, heart, pleura (mediastinal 
lymph  node),  appendix,  pancreas.  A  comparison 
of adenomatoid tumors of sites other than testes is 
detailed in the Table 1.
Histopathology
Adenomatoid tumors show a spectrum of histological 
patterns as adenoid or tubular glandular, angiomatoid, 
solid, cystic or transitional forms of all four above 
histological patterns.4 Microscopically, tumors appear 
as eosinophilic mesothelial cells in pattern of solid 
cords as well as dilated tubules that may look like 
endothelium in origin (Figs. 1 and 2). The pathognomic 
feature of the cells is a vacuolated cytoplasm with 
cytologic  atypia  (Fig.  3).  Mitoses  are  typically  not 
present. In most of the lesions, the stroma is fibrous but 
may occasionally contain a smooth muscle component 
(Fig.  2).2,8  This  tumor  is  generally  unencapsulated 
therefore  their  pattern  of  growth  is  uncharacteristic 
of  benign  neoplasms  and  frequently  invade  the 
surrounding tissue (Fig. 1).15 AT cells attain positively 
for  Hyaluronidase  sensitive  muco-substance  (HSM) 
with Alcian blue stain.5
immunohistochemistry
Immunohistochemical test show a presence of WT1 
gene expression, calretinin (a 29-kilodalton, calcium 
binding protein is a specific marker for mesothelial 
cells and mesothelioma) and vimentin.4 They have also Adenomatoid tumor of testis
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been  reported  to  show  positivity/reactivity  for  high 
and low molecular weight cytokeratin (CK), EMA and 
primary mesothelial monoclonal antibody HBME-1.5
Adenomatoid  tumors  show  non-reactivity  for 
epithelial/carcinoma markers CEA CD 15 (Leu M1) 
B72.3 MOC-31, Ber-ep4, LeA 135, factor VIII, CD34, 
Absence of staining for hemangioma (H) associated 
antigens  factor  VII  and  CD  34  excludes  vascular 
tumors and mesenchymal lesions. Absence of inhibin 
expression  helps  exclude  adrenal  cortical  and  sex 
cord-stromal neoplasms.16
Diagnosis
Ultrasonography  reveals  the  nature  of  the  lesion 
which  is  usually  hypoechoic  and  solid.  During 
ultrasonography  a  real  time  maneuver  can  be 
performed by the radiologist with the probe in one 
hand and pushing the testes downwards with a finger 
of the free hand. If the testes displace downwards and 
the mass remains at its site then it is concluded that 
the mass is paratesticular. This facilitates preoperative 
assessment and organ sparing surgery.
Absence  of  serum  tumor  markers  like  B-HCG, 
CEA,  alpha-fetoprotein  and  LDH  help  to  exclude 
malignant  lesion.  Histological  evaluation  of  the 
specimen results in definitive diagnosis which is also 
supported by immunohistochemistry.
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Figure 1. A low power view of a paratesticular adenomatoid tumor. Note 
the dilated tubules giving the appearance of endothelial spaces, adjacent 
to the normal uninvolved testicular parenchyma (4x, H & e).Adenomatoid tumor of testis
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Magnetic  Resonance  Imaging  (MRI)  finding 
are  helpful  in  pre-operatively  determining  if  the 
palpable  mass  is  originating  from  the  albuginea 
of the testes or from the surrounding seminiferous 
tubules.  Typically  the  scrotal  MRI  is  executed 
using fast spin echo T2 weighted images in axial 
and  sagittal  planes.  Unenenhanced  and  dynamic 
gadolinium-enhanced-gradient  echo  T1  weighted 
images  are  captured  in  axial  plane  and  followed 
30, 60 and 90 seconds after contrast administration 
and  delayed  gadolinium—enhances  gradient  echo 
T1-weighted images in sagittal and axial planes. A lens 
shaped mass is seen on unenhanced images originating 
from the testicular surface, the mass is somewhat 
hypointense  in  comparison  with  the  testicular 
parenchyma. Dynamic and delayed enhanced images 
show thin uniform band of hypointense parenchyma 
around  the  mass  showing  early  and  persistent 
enhancement.17  Dynamic  contrast  enhanced  MRI 
studies are helpful in differentiating testicular tumors 
from other testicular disorders.18
Abdominal CT is helpful in identifying extra genital 
adenomatoid  tumors.  Solitary  hepatic  adenomatoid 
tumor can be detected on routine abdominal ultrasound 
presenting as a hypervascular hyperechogenic tumor.9 
For adenomatoid tumors arising in the adrenal gland 
MRI and CT are helpful in revealing the mass and 
detailing its extent and invasion.11
Differantial Diagnosis
The  differential  diagnoses  include  adenocarcinoma 
of  testes,  hemangioma,  malignant  mesothelioma, 
yolk  sac  tumor,  metastatic  carcinoma  of  prostate, 
lymphoma and other testicular masses and tumors.
Management and prognosis
Excision  biopsy  is  considered  both  diagnostic  and 
therapeutic  procedure.  Adenomatoid  tumors  have 
not  been  known  to  ever  recur  or  show  malignant 
degeneration.4  The  adequate  use  of  tumor  marker 
studies,  utrasonography  and  intraoperative  frozen 
sections can facilitate organ sparing surgery. The aim 
is to prevent unnecessary orchiectomy resulting in 
continuation of endogenous testosterone production 
and preserving fertility.8
conclusion
This  rare,  benign  neoplasm  provides  a  clinical 
diagnostic  challenge  with  the  aim  to  preserve 
endogenous  testicular  function.  Recent  research 
suggests  its  origin  to  be  mesothelial  even  though 
these  tumors  occur  in  hormone  responsive  organ 
but no hormone receptors have been discovered in 
adenomatoid tumors and there is no proof that these 
are hormone sensitive.
Figure 2. Higher power view showing the tubular pattern of growth with 
dilated  spaces  and  intervening  fibrous  stroma  with  a  smooth  muscle 
component (20x H & e).
Figure 3. A higher power view of the neoplasm with predominant component 
consisting  of  tubules  with  intervening  single  cells  with  a  vacuolated 
appearance, a characteristic finding in adenomatoid tumors (40x, H & E).Amin and Parwani
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